Drugmakers report product-led growth as the White House claims prices are falling fast

A strong quarter on products

Pfizer reported third-quarter 2026 revenues of $16.6 billion, the company says, and raised its full-year 2026 revenue guidance to a range of $62.0 billion to $64.0 billion, with adjusted diluted earnings-per-share guidance of $2.95 to $3.05. The company says its non-COVID products delivered 7% operational revenue growth in the quarter, and its launched and acquired products grew 32% operationally. It also reported third-quarter adjusted diluted earnings per share of $0.87, against reported diluted earnings per share of $0.56. m:…8096

The company also appointed Cecile Guegan as Financial Officer and Executive Vice President, recorded a one-time $650 million Acquired In-Process R&D charge related to the Innovent Biologics in-licensing agreement, and says it deployed approximately $850 million in business development transactions during the first nine months of 2026. None of those disclosures attributes the quarter's growth to price changes in either direction. m:…8096

Amneal Pharmaceuticals reported Q3 2026 net revenue of $863 million and Adjusted EBITDA of $207 million, the company says, alongside a GAAP net loss of $22 million. Affordable Medicines net revenue increased 19% and Specialty net revenue increased 20%, while AvKARE net revenue decreased 17%. The company updated its full-year 2026 net revenue guidance to $3.15 billion to $3.25 billion. m:…7403

Smaller names, same pattern

Madrigal Pharmaceuticals reported Q3 2026 net revenues of $431.3 million, the company says, and achieved its first quarter of profitability with $55.4 million in net income. Its drug Rezdiffra reached $1.1 billion in year-to-date net sales, and the company says more than 55,850 patients were on Rezdiffra as of September 30, 2026. It reported cash, cash equivalents, restricted cash and marketable securities of $961.8 million as of the same date. m:…3293

Rhythm Pharmaceuticals reported Q3 2026 global net product revenue of $92.1 million, the company says, with U.S. revenue of $67.5 million, an increase of 32% compared with the second quarter of 2026. The company entered a five-year term loan facility providing access to up to $750 million, amended its license agreement with LG Chem to pay $350 million over four years in exchange for a reduced 1% royalty rate, and says it received more than 700 patient start forms for IMCIVREE for acquired HO as of September 30, 2026. m:…1299

IDEAYA Biosciences, by contrast, filed a quarter defined more by pipeline moves than by product revenue: it reported $1.15 billion in cash, cash equivalents and marketable securities as of September 30, 2026, submitted a new drug application to the FDA for the darovasertib combination in metastatic uveal melanoma, and decided to stop enrollment and close the Phase 3 OptimUM-010 trial due to site activation and enrollment challenges, a closure it expects to produce cost savings of $100 million to $125 million. m:…4058

IDEAYA says it expects its cash runway to extend into 2030 based on its current operating plan, and it has initiated a global Phase 3 registrational trial, OptimUM-011, with Les Laboratoires Servier to evaluate the darovasertib combination in the adjuvant setting. This suggests the growth story in this batch of filings is product and patient volume at the larger names, and cash runway and pipeline positioning at the earlier-stage one — not a single industry-wide explanation. m:…4058

The price claim from Washington

The White House, in a post headed ICYMI, says prescription drug prices fell 4.5% year over year, which it describes as the largest decline since 1963. The administration also says nonprescription drug prices fell 0.9% year over year, while overall consumer prices rose 3.7% year over year. These are administration claims, not figures from the companies' filings, and the post does not publish the underlying price index or methodology in the available claims. m:…2596

The administration ties its claim to specific programs: it says the TrumpRx program was launched in February 2026, provides cash-paying patients with discounts on over 800 drugs, and that agreements with Eli Lilly and Novo Nordisk reduce the cost of GLP-1 medications for government programs and TrumpRx. It also says Medicare coverage for obesity treatment has been expanded with a $50 monthly copay, and that U.S. prescription drug spending on the GLP-1 drugs tirzepatide and semaglutide reached approximately $60 billion each in 2025. m:…2596

What the two pictures do not settle

Read side by side, the two pictures sit in tension but do not explain each other. The companies' filings report revenue growth, patient counts and raised guidance; they do not say prices fell, and they do not credit any administration program with their results. The White House post claims prices fell; it does not address these companies' quarterly results, and it does not name Pfizer, Amneal, Madrigal, Rhythm or IDEAYA. m:…8096 m:…3293 m:…1299 m:…2596

This suggests the honest reading is narrower than either headline alone: product-led revenue growth and a claimed fall in an aggregate price measure can coexist if volume, product mix or newly launched products drive revenue while prices on some basket of drugs fall — but the available evidence does not establish that explanation, and it should not be presented as one. What would settle it is the price and volume breakdown behind both the filings and the administration's claim, and neither set of documents provides it. m:…8096 m:…3293 m:…2596